ERBB2 and breast carcinoma: Attempts to improve on the results of treatment of HER2-positive breast cancer, have principally involved the incorporation of additional anti-HER2 drugs into existing regimens.9,10 There has been less focus on the possibility that optimised scheduling might improve outcomes.